Obesity drugs are rapidly moving from the margins of lifestyle care to the centre of India’s pharmaceutical growth story as rising lifestyle diseases, new blockbuster launches and the looming entry of low-cost generics reshape the market. With global consultants McKinsey ranking obesity therapies alongside AI, electric vehicles and robotics as trillion-dollar opportunities by 2040, India…
Mumbai: Emcure Pharmaceuticals has announced the commercial launch of the second brand of Danish drug maker Novo Nordisk‘s popular GLP-1 weight management medication. Emcure is the first Indian company to exclusively distribute and commercialise Poviztra. Poviztra will be available at a starting price ₹8,790 for the lowest dosage for a month’s treatment of four shots….
Emcure Pharmaceuticals on Monday announced the commercial launch of Poviztra, a semaglutide injection for weight loss, across India. With this launch, Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, which is Novo Nordisk’s second brand of semaglutide for weight management, the company said in a statement. Poviztra will be available in…
Pune-based Emcure Pharmaceuticals has reported 13.4% year-on-year increase in consolidated revenue to Rs 2,270 crore, driven by double-digit growth across both domestic and international markets. Profit after tax (PAT) jumped 24.7% YoY to Rs 251 crore, while EBITDA grew 15.2% to Rs 439 crore, translating to an EBITDA margin of 19.3%, the company said in…
Novo Nordisk has partnered with India‘s Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug under a new brand in the country, the companies said on Monday. Under the agreement, the Danish drugmaker will sell Poviztra 2.4 milligram (mg) semaglutide injection in India as a separate brand of its blockbuster weight-loss treatment Wegovy. Shares…
CDSCO Panel Approves Emcure’s Phase III Clinical Trial of Semaglutide, Mandates Govt Trial Sites We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
India’s pharma sector is at a turning point transitioning from a global generics powerhouse to a serious contender in biotech and innovation. In this episode, host Vikas Dandekar is joined by Namita Thapar, Executive Director, Emcure Pharmaceuticals, Aman Mehta, Managing Director, Torrent Pharma, and Sharvil Patel, Managing Director, Zydus Lifesciences to explore what it takes…